ProShares - UltraShort Nasdaq Biotechnology (BIS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ProShares - UltraShort Nasdaq Biotechnology (BIS) trades at $11.12 with AI Score 47/100 (Grade C). ProShares UltraShort Nasdaq Biotechnology (BIS) is an exchange-traded fund (ETF) designed to deliver twice the inverse of the daily… Market cap: $1.78M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BIS: BIS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIS against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BIS: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ProShares - UltraShort Nasdaq Biotechnology (BIS) Financial Services Profile
ProShares UltraShort Nasdaq Biotechnology (BIS) offers a leveraged inverse exposure to the Nasdaq Biotechnology Index, targeting sophisticated investors seeking short-term hedging or speculative opportunities within the volatile biotech sector. It is important to understand the risks associated with leveraged and inverse ETFs before investing.
What Is the Investment Thesis for BIS?
BIS presents a tactical opportunity for investors with a short-term bearish outlook on the biotechnology sector. By providing -2x daily inverse exposure to the Nasdaq Biotechnology Index, BIS can generate gains when the index declines. However, the leveraged nature of the fund amplifies both gains and losses, making it a high-risk investment. Investors should closely monitor the biotech sector and be prepared to actively manage their positions. The fund's performance is highly sensitive to daily market movements, and its suitability for long-term investment is questionable due to the effects of compounding and volatility. A key consideration is the potential for rapid erosion of capital if the Nasdaq Biotechnology Index moves against the intended direction.
Based on FMP financials and quantitative analysis
BIS Key Highlights
BIS seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index.
- The fund is designed for short-term tactical positioning rather than long-term investment strategies.
- BIS is managed by ProShare Advisors LLC, a leading provider of alternative ETFs.
- The fund's beta is -1.47, indicating a high degree of inverse correlation with the Nasdaq Biotechnology Index.
- BIS does not offer a dividend yield, as its primary objective is to provide leveraged inverse exposure.
Who Are BIS's Competitors?
BIS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BULG Leverage Shares 2x Long BULL Daily ETF | $55.57 | +5.23% | 46 | |
| ALISR Calisa Acquisition Corp Right | $0.64 | +0.00% | 79 | |
| IDKFF ThreeD Capital Inc. | $0.07 | +13.85% | $6.98M | 70 |
| ALTEX Firsthand Alternative Energy Fund | $12.93 | -1.90% | $8.98M | 82 |
| BCG Binah Capital Group, Inc. | $1.40 | +0.72% | $23.5M | 78 |
| EEA The European Equity Fund, Inc. | $11.15 | -0.59% | $74.7M | 67 |
| HNNA Hennessy Advisors, Inc. | $9.89 | -1.30% | $78.2M | 81 |
| ETHT ProShares - Ultra Ether ETF | $12.57 | +19.94% | $92.2M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIS's Key Strengths?
Provides a convenient way to gain leveraged inverse exposure to the Nasdaq Biotechnology Index.
- Offers a tool for hedging against potential losses in biotech portfolios.
- Managed by ProShare Advisors LLC, a reputable provider of alternative ETFs.
- High inverse correlation with the Nasdaq Biotechnology Index, as indicated by its beta.
What Are BIS's Weaknesses?
Leveraged nature amplifies both gains and losses, making it a high-risk investment.
- Not suitable for long-term investment due to the effects of compounding and volatility.
- Performance is highly sensitive to daily market movements.
- Subject to management fees and expenses, which can reduce returns.
What Could Drive BIS Stock Higher?
BIS catalyst: Clinical trial results in the biotechnology sector can significantly impact stock prices, creating opportunities for BIS.
- Regulatory decisions by the FDA regarding drug approvals can drive volatility in the biotech market.
- Macroeconomic factors, such as interest rate changes and inflation, can influence investor sentiment towards growth stocks like those in the biotech sector.
What Are the Key Risks for BIS?
The leveraged nature of BIS amplifies both gains and losses, making it a high-risk investment.
- The fund is not suitable for long-term investment due to the effects of compounding and volatility.
- Unexpected positive developments in the biotechnology sector could lead to losses.
- Changes in regulations governing leveraged and inverse ETFs could impact its operations.
- Competition from other similar products could reduce its market share.
What Are the Growth Opportunities for BIS?
- Increased Volatility in the Biotech Sector: The inherent volatility of the biotechnology sector, driven by factors like clinical trial results and regulatory decisions, can create opportunities for BIS. As uncertainty increases, more investors may seek to hedge their biotech holdings or speculate on potential downturns, driving demand for BIS. The market size for biotech-related hedging instruments is directly tied to the overall market capitalization of the biotech industry, which can fluctuate significantly. Timeline: Ongoing.
- Rising Interest Rate Environment: Rising interest rates can negatively impact growth stocks, including those in the biotechnology sector, as higher rates reduce the present value of future earnings. This could lead to a decline in biotech stock prices, benefiting BIS. The impact of interest rates on the biotech sector is a key factor influencing the demand for inverse ETFs like BIS. Timeline: Ongoing.
- Expansion of Inverse ETF Market: The overall market for inverse ETFs is growing as investors seek more sophisticated tools for managing risk and expressing bearish views. As awareness of these products increases, BIS could attract a larger pool of investors. The growth of the inverse ETF market is driven by factors such as market volatility and investor sentiment. Timeline: Ongoing.
- Strategic Partnerships with Brokerage Firms: ProShares could partner with brokerage firms to promote BIS to their clients, increasing its visibility and accessibility. These partnerships could involve educational initiatives or preferential trading terms. The success of these partnerships depends on the ability to effectively communicate the risks and benefits of BIS to potential investors. Timeline: Ongoing.
- Development of New Biotech Sub-Indices: The creation of new, more specialized biotech sub-indices could lead to the development of new inverse ETFs targeting specific segments of the biotech industry. This could allow ProShares to offer more tailored products to investors with specific views on the biotech sector. The feasibility of this opportunity depends on the demand for more granular biotech exposure. Timeline: Ongoing.
What Are BIS's Competitive Advantages?
- Brand recognition and reputation of ProShares as a leading provider of alternative ETFs.
- Established track record of providing leveraged and inverse exposure to various indices.
- Expertise in managing complex financial instruments and derivatives.
- First-mover advantage in offering a leveraged inverse ETF focused on the Nasdaq Biotechnology Index.
What Does BIS Do?
ProShares UltraShort Nasdaq Biotechnology (BIS) is an exchange-traded fund (ETF) managed by ProShare Advisors LLC. It was created to provide investors with a way to achieve daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index. This index comprises a selection of securities listed on the NASDAQ that are classified as biotechnology companies, making BIS a specialized tool for those with a view on the short-term direction of the biotech market. The fund is not designed for long-term investing and is best suited for sophisticated investors who understand the risks associated with leveraged and inverse ETFs. These types of funds can experience significant volatility and may not perform as expected if held for longer than a single day due to the effects of compounding. ProShares, as a company, is a leading provider of alternative ETFs, offering a range of products designed to help investors manage risk and enhance returns. Their focus is on providing tools that allow investors to express specific market views, whether bullish, bearish, or neutral.
What Products and Services Does BIS Offer?
- Provides leveraged inverse exposure to the Nasdaq Biotechnology Index.
- Offers a tool for investors to profit from declines in the biotechnology sector.
- Allows investors to hedge against potential losses in their biotech portfolios.
- Seeks daily investment results that are two times the inverse of the index's performance.
- Provides short-term tactical investment opportunities.
- Offers a way to express a bearish view on the biotechnology market.
How Does BIS Make Money?
- Generates revenue through management fees charged on the assets under management (AUM).
- Aims to track the daily performance of two times the inverse of the Nasdaq Biotechnology Index.
- Utilizes derivatives and other financial instruments to achieve its investment objective.
- Rebalances its portfolio daily to maintain the desired leverage ratio.
What Industry Does BIS Operate In?
The asset management industry is highly competitive, with numerous firms offering a wide range of investment products, including ETFs. Inverse and leveraged ETFs like BIS cater to a niche market of sophisticated investors seeking to express short-term market views. The biotechnology sector itself is characterized by high growth potential but also significant volatility due to factors such as clinical trial outcomes, regulatory approvals, and patent expirations. BIS provides a tool for investors to potentially profit from or hedge against this volatility. Competitors offer similar leveraged and inverse products across various sectors and asset classes.
Who Are BIS's Key Customers?
- Sophisticated investors seeking short-term tactical opportunities.
- Hedge funds and other institutional investors.
- Financial advisors managing client portfolios.
- Traders looking to profit from short-term declines in the biotechnology sector.
How ProShares - UltraShort Nasdaq Biotechnology Is Valued
ProShares - UltraShort Nasdaq Biotechnology carries a market capitalization of $1.78M, placing it in the micro-cap category. Relative to its peer group, BIS's quantitative score of 47/100 is below the peer average of 71/100.
Key Financial Metrics
Return on equity for ProShares - UltraShort Nasdaq Biotechnology stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. BIS trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
BIS Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's strategy, indicating potential for positive market movement.
- Community sentiment has shifted positively as biotech stocks show signs of recovery, leading to increased interest in short positions.
- Market perception around the biotech sector remains cautious, which could drive demand for hedging through products like BIS.
- The ongoing volatility in the Nasdaq biotechnology space creates opportunities for short strategies, aligning with market trends.
Bear Case
- Increased optimism in the biotech sector may lead to reduced demand for short products like BIS, as traders look for growth.
- Recent sentiment analysis shows a growing bullish outlook on major biotech stocks, which could limit BIS's appeal.
- The ongoing recovery in biotech could result in losses for short positions, especially if momentum builds in the sector.
- Community discussions indicate skepticism about the sustainability of short positions in a potentially rebounding market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BIS Latest News
No recent news available for BIS.
BIS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIS.
Price Targets
Wall Street price target analysis for BIS.
BIS MoonshotScore
What does this score mean?
The MoonshotScore rates BIS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
BIS Financial Services Stock FAQ
What does the AI Score mean for BIS?
BIS holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. ProShares UltraShort Nasdaq Biotechnology (BIS) is an exchange-traded fund (ETF) designed to deliver twice the inverse of the daily performance of the Nasdaq Biotechnology Index. It provides …
What does ProShares - UltraShort Nasdaq Biotechnology do?
ProShares UltraShort Nasdaq Biotechnology (BIS) is designed to deliver twice the inverse of the daily performance of the Nasdaq Biotechnology Index. It is an exchange-traded fund (ETF) that uses financial instruments, including derivatives, to achieve its objective. BIS is intended for sophisticated investors seeking short-term tactical opportunities to profit from, or hedge against, declines in the biotechnology sector.
What do analysts say about BIS stock?
Given that BIS is an inverse ETF, analyst ratings typically focus on the outlook for the underlying Nasdaq Biotechnology Index rather than the fund itself. A bearish outlook on the biotech sector would generally be seen as favorable for BIS, while a bullish outlook would be seen as unfavorable.
What are the main risks for BIS?
The primary risk associated with BIS is the potential for amplified losses due to its leveraged nature. Because it seeks to deliver two times the inverse of the daily performance of the Nasdaq Biotechnology Index, any unexpected positive movement in the biotech sector can result in significant losses.
How does BIS perform in different market conditions?
BIS is designed to perform well when the Nasdaq Biotechnology Index declines. In a falling market, BIS should generate positive returns, although the actual returns may differ from the stated -2x leverage due to factors such as fees, expenses, and daily rebalancing. However, in a rising market, BIS is expected to lose value.
What are the fees associated with investing in BIS?
As an exchange-traded fund, BIS charges management fees and other expenses, which are typically expressed as an expense ratio. This expense ratio represents the percentage of the fund's assets that are used to cover its operating costs. Investors should carefully review the fund's prospectus to understand all the fees and expenses associated with investing in BIS.
What are the key factors to evaluate for BIS?
ProShares - UltraShort Nasdaq Biotechnology (BIS) holds an AI score of 47/100 (low). BIS presents a tactical opportunity for investors with a short-term bearish outlook on the biotechnology sector. Not financial advice.
How frequently does BIS data refresh on this page?
BIS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BIS's recent stock price performance?
ProShares - UltraShort Nasdaq Biotechnology (BIS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Provides a convenient way to gain leveraged inverse exposure to the Nasdaq Biotechnology Index. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, which may provide further insights into the company's performance and outlook.
- Leveraged and inverse ETFs are complex financial instruments and are not suitable for all investors.
- Past performance is not indicative of future results.